Literature DB >> 28501512

Anti-influenza activity of monoterpene-containing substituted coumarins.

Tatyana M Khomenko1, Vladimir V Zarubaev2, Iana R Orshanskaya3, Renata A Kadyrova3, Victoria A Sannikova1, Dina V Korchagina4, Konstantin P Volcho1, Nariman F Salakhutdinov1.   

Abstract

Compounds simultaneously carrying the monoterpene and coumarin moieties have been tested for cytotoxicity and inhibition of activity against influenza virus A/California/07/09 (H1N1)pdm09. The structure of substituents in the coumarin framework, as well as the structure and the absolute configuration of the monoterpenoid moiety, are shown to significantly influence the anti-influenza activity and cytotoxicity of the compounds under study. The compounds with a bicyclic pinane framework exhibit the highest selectivity indices (the ratios between the cytotoxicity and the active dose). The derivative of (-)-myrtenol 15c, which is characterized by promising activity, low cytotoxicity, and synthetic accessibility, has the greatest potential among this group of compounds. It exhibited the highest activity when added to the infected cell culture at early stages of viral reproduction.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-influenza activity; Antivirals; Aurapten; Coumarin; Cytotoxicity; Influenza A virus; Myrtenal; Terpene

Mesh:

Substances:

Year:  2017        PMID: 28501512     DOI: 10.1016/j.bmcl.2017.04.091

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  New chemical agents based on adamantane-monoterpene conjugates against orthopoxvirus infections.

Authors:  Evgenii V Suslov; Evgenii S Mozhaytsev; Dina V Korchagina; Nikolay I Bormotov; Olga I Yarovaya; Konstantin P Volcho; Olga A Serova; Alexander P Agafonov; Rinat A Maksyutov; Larisa N Shishkina; Nariman F Salakhutdinov
Journal:  RSC Med Chem       Date:  2020-08-06

2.  Synthesis of d-(+)-camphor-based N-acylhydrazones and their antiviral activity.

Authors:  Kseniya S Kovaleva; Fedor I Zubkov; Nikolay I Bormotov; Roman A Novikov; Pavel V Dorovatovskii; Victor N Khrustalev; Yuriy V Gatilov; Vladimir V Zarubaev; Olga I Yarovaya; Larisa N Shishkina; Nariman F Salakhutdinov
Journal:  Medchemcomm       Date:  2018-10-26       Impact factor: 3.597

3.  Promising New Inhibitors of Tyrosyl-DNA Phosphodiesterase I (Tdp 1) Combining 4-Arylcoumarin and Monoterpenoid Moieties as Components of Complex Antitumor Therapy.

Authors:  Tatyana M Khomenko; Alexandra L Zakharenko; Arina A Chepanova; Ekaterina S Ilina; Olga D Zakharova; Vasily I Kaledin; Valeriy P Nikolin; Nelly A Popova; Dina V Korchagina; Jóhannes Reynisson; Raina Chand; Daniel M Ayine-Tora; Jinal Patel; Ivanhoe K H Leung; Konstantin P Volcho; Nariman F Salakhutdinov; Olga I Lavrik
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

Review 4.  Pharmacological perspectives and molecular mechanisms of coumarin derivatives against virus disease.

Authors:  Zhoupeng Li; Dehui Kong; Yongsheng Liu; Mingkai Li
Journal:  Genes Dis       Date:  2021-04-20

5.  Coumarin: An emerging antiviral agent.

Authors:  Shruti Mishra; Achyut Pandey; Siddharth Manvati
Journal:  Heliyon       Date:  2020-01-27

6.  Monoterpene-Containing Substituted Coumarins as Inhibitors of Respiratory Syncytial Virus (RSV) Replication.

Authors:  Tatyana M Khomenko; Anna A Shtro; Anastasia V Galochkina; Yulia V Nikolaeva; Galina D Petukhova; Sophia S Borisevich; Dina V Korchagina; Konstantin P Volcho; Nariman F Salakhutdinov
Journal:  Molecules       Date:  2021-12-10       Impact factor: 4.411

7.  Novel Bispidine-Monoterpene Conjugates-Synthesis and Application as Ligands for the Catalytic Ethylation of Chalcones.

Authors:  Evgeniy V Suslov; Konstantin Y Ponomarev; Oxana S Patrusheva; Sergey O Kuranov; Alina A Okhina; Artem D Rogachev; Aldar A Munkuev; Roman V Ottenbacher; Alexander I Dalinger; Mikhail A Kalinin; Sergey Z Vatsadze; Konstantin P Volcho; Nariman F Salakhutdinov
Journal:  Molecules       Date:  2021-12-13       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.